Robust consolidation activity among outsourced pharmaceutical providers, particularly Contract Development and Manufacturing Organizations (CDMOs) and Contract Research Organizations (CROs), has been driven by pharmaceutical companies seeking to reduce costs and obtain expertise and talent associated with all phases of drug development and production.  Available for download below, Capstone Headwaters has released its Q4 Pharmaceutical Outsourcing Executive Summary.  The report includes:

• M&A Segment Breakdown
• Analytical Testing Highlight
• Notable Transactions

To learn more about the report, please reach out to Managing Director Eric Williams

Get instant access to reports like this as they're published. Subscribe